Development of a recombinant, chimeric tetravalent dengue vaccine candidate

IgG, IgM, and nonstructural protein 1 response profiles after receipt of tetravalent dengue vaccine TAK-003 in a phase 2 randomized controlled trial

Antibodies produced in response to a live-attenuated dengue vaccine are functional in activating the complement system

Rebuttal to de Silva A. J Infect Dis. 2022 letter: Reply to de Silva and White

Neutralization fingerprinting technology for characterizing polyclonal antibody responses to dengue vaccines

Specificity and breadth of the neutralizing antibody response to a live-attenuated tetravalent dengue vaccine

Development of a novel assay to assess the avidity of dengue virus-specific antibodies elicited in response to a tetravalent dengue vaccine

Long term T cell response and safety of a tetravalent dengue vaccine in healthy children

Reply to: Editorial “The increasing use of T-cell stimulation for successful dengue vaccination” in eBioMedicine 2024; 102, 105120

Characterization of the cell-mediated immune response to Takeda's live-attenuated tetravalent dengue vaccine in adolescents participating in a phase 2 randomized controlled trial conducted in a dengue-endemic setting

A recombinant, chimeric tetravalent dengue vaccine candidate based on a dengue virus serotype 2 backbone

Development of a recombinant, chimeric tetravalent dengue vaccine candidate

CD8+ T-cell responses in flavivirus-naïve individuals following immunization with a live-attenuated tetravalent dengue vaccine candidate